Aa
Aa
A
A
A
Close
Avatar universal

Got an email from Replicor

Trial will start very soon in Europe. It Is expected elemination of Hbsag within 10 weeks and antibodies production rapidly after. Cure is  here,clear and soon !
29 Responses
Sort by: Helpful Oldest Newest
Avatar universal
No problem on the rant, I completely understand. I am fortunate to comfirm recently that I did not contract HBV as I was worried for quite a while. However I am very sympathetic to everyone here and I have learned a lot in the past 5 months.

I am considering a private investment in Replicor after I spoke I the CEO yesterday. I am happy for my money to help fund a new study to prove this drug works and speed the development of a potential cure. I also wouldn't mind making a few bucks in the process, it might make up for some of the anxiety of the past few months. I am going to call Michel back next week as I have a few more questions I have been compiling before I commit.

If anyone has anything they would like me to ask I would be glad to do so
Helpful - 0
Avatar universal
Hi Thanks for the info

Sorry if it seemed like I was ranting before I feel like I'm just getting so frustrated at the pace things move the longer we have this in our bodies the worse it is.

But this will be great if Gilead bought it and then took REP9AC' and expanded the trials and bought onto the market. that would be a weight of my shoulders as I'm sure it would be weight off everyone elses here to :)

Fingers crossed the phase 2 is as successful as phase 1.

Helpful - 0
Avatar universal
Thank you for ringing and for the new information.
Helpful - 0
Avatar universal
Great! , And few days ago Gilead reported $2.3 billions in sales of Sovaldi only for 3 first months on market. I think that researchers from Gilead will not let go easy when they will see results, and will expands trials all around.
Helpful - 0
Avatar universal
I don't believe that there is some grand conspiracy going on with the drug companies, if there was Sovaldi wouldn't have seen the light of day.

I spoke to the CEO today and they will be starting in Europe this summer, he told me that many drug companies (including Gilead) have approached them but they want to see that it works and they aren't convinced as the last trial was run by Replicor themselves. For this trial Replicor will only supply the drug and researchers will run the trial. He also told me they are going to focus on HDV and use the orphan drug status to speed things along. He anticipates 20 weeks to results of the  first two components of the trial, at that time they think big pharma will buy it and provide further development.
Helpful - 0
Avatar universal
Something proper weird is going on.

Its  not only Europe  its only GERMANY. So anyone else is screwed!

To be honest it makes perfect sense to the drug companies flogging us NUCS!!

Replicor say its taking so long due to "Bureaucracy" Well I'd love to  hear what that is.

I can only think something isn't right either with the product or circumstances surrounding my suspicion is the second one!

It seems like people with Hep B have just been stuffed in the background and forgotten about. If we complain or our voices we get a whole bunch of  clever  answers about how its very complicated bla bla and how we should be grateful that there doing anything at all.

Grateful? loads of people are dying but don't forget to be grateful! LAUGHABLE in the saddest possible way.

Replicor is clearly what we  need but absolutely no one is interested keep the gravy train of cash flowing choo choo!!
Helpful - 0
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.